|
Patient and Healthcare Provider Convenience Focus of Packaging Enhancements for Humate-P from CSL Behring
November 9, 2009
Read Press Release
National Hemophilia Foundation Applauds First von Willebrand Disease Clinical Practice Guidelines Issued by NHLBI
May 6, 2008
Read Press Release
Humate-P® Package Notification
Wednesday, July 25, 2007
Read Press Release
Humate-P® Approved to Prevent Excessive Bleeding in VWD Patients
Undergoing Surgery
Monday, April 30, 2007
Read Press Release
Updated Prescribing Information
CSL Behring Announces Availability of Humate-P® with Smaller Diluent
Wednesday, February 15, 2006
Read Press Release
To stay informed about the latest news in hematology and bleeding
disorders, you or your patients may be interested in attending the conferences and meetings
listed below. CSL Behring will be participating in all of these events, so please stop
by our exhibit booth and get information on Humate-P®, speak with a CSL Behring representative,
or obtain brochures.
Hemophilia Federation of America
HFA 2009 Annual Educational Symposium
March 13-14, 2009
Mariott East
Indianapolis, IN
www.hemophiliafed.org
Hemophilia & Thrombosis Research Society
2009 HTRS/NASCOLA Annual Scientific Symposium
April 16-18, 2009
Chicago, Illinois
www.htrs.org
International Society on Thrombosis & Haemostasis
XXII ISTH Congress
July 11-17, 2009
Boston Convention & Exhibition Center
Boston, MA
www.isth2009.com
National Hemophilia Foundation
Annual Meeting
October 29-31, 2009
San Francisco, CA
www.hemophilia.org
The American Society of Hematology
51st Annual Meeting and Exposition
December 5-8, 2009
Ernest N. Morial Convention Center
New Orleans, LA
www.hematology.org
*Upcoming conference dates will be posted when they become available.
Most local hemophilia chapters have a Web site, which typically includes a calendar of events. To find a chapter near you, go to the National Hemophilia Foundation Web site at:
www.hemophilia.org/chapters
Important Safety Information
Antihemophilic Factor/von Willebrand Factor Complex (Human), Dried, Pasteurized, Humate-P® is indicated in adult patients for treatment and prevention of bleeding in hemophilia A (classical hemophilia). Humate-P® is also indicated in adult and pediatric patients with von Willebrand disease (VWD) for (1) treatment of spontaneous and trauma-induced bleeding episodes, and (2) prevention of excessive bleeding during and after surgery. This applies to patients with severe VWD, and patients with mild and moderate VWD for whom use of desmopressin is known or suspected to be inadequate.
Humate-P® is contraindicated in individuals with a history of anaphylactic or severe systemic response to antihemophilic factor or von Willebrand factor preparations, or to any of its components.
Thromboembolic events have been reported in VWD patients receiving coagulation factor replacement, especially in the setting of known risk factors for thrombosis. Caution should be exercised and antithrombotic measures considered.
Humate-P® is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.
The most common adverse reactions reported in patients receiving Humate-P® are allergic-anaphylactic reactions, including urticaria, chest tightness, rash, pruritus, edema, shock, chills and fever, and hypervolemia. For patients undergoing surgery, the most common adverse reactions are postoperative wound or injection-site bleeding.
Please see full prescribing information.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
The information provided herein is solely for use by physicians and healthcare professionals in the United States. The CSL Behring product listed may not have been approved in other countries and may not be available everywhere.
|||
||
© CSL Behring 2010. The product information presented on this site is intended for US residents only.
|
